Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2004 May 17;199(10):1421–1431. doi: 10.1084/jem.20040191

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2004, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 8. — (A) Effect of MHC–peptide stripping and cycloheximide treatment on ex vivo intracellular IFN-γ production by EBNA1-specific T cells. PBMCs from an HLA B35⁺ donor were incubated alone or with either an HLA B*3501⁺ LCL, an HLA B*3501⁺ LCL plus 0.01 μM HPV peptide, an HLA B*3501⁺ LCL treated with citrate buffer and 50 μM cycloheximide, an HLA B*3501⁺ LCL treated with citrate buffer, or an HLA LHLA B*3501⁺ LCL treated with cycloheximide. Data shown represents the CD8⁺ and tetramer⁺ population (solid bars) and the tetramer⁺ population producing IFN-γ (shaded bars). This data is a representation of two separate experiments. (B) Surface MHC class I expression on untreated LCLs or LCLs treated with either cycloheximide, citrate buffer alone, or cycloheximide and citrate buffer. LCLs were initially incubated with MHC class I–specific mAb (W6/32) followed by incubation with FITC-labeled anti–mouse Ig. The fluorescence intensity was measured by FACSCalibur™ and data were analyzed by CELLQuest™ software. The results are expressed as mean fluorescence intensity.

Figure 8. — (A) Effect of MHC–peptide stripping and cycloheximide treatment on ex vivo intracellular IFN-γ production by EBNA1-specific T cells. PBMCs from an HLA B35⁺ donor were incubated alone or with either an HLA B*3501⁺ LCL, an HLA B*3501⁺ LCL plus 0.01 μM HPV peptide, an HLA B*3501⁺ LCL treated with citrate buffer and 50 μM cycloheximide, an HLA B*3501⁺ LCL treated with citrate buffer, or an HLA LHLA B*3501⁺ LCL treated with cycloheximide. Data shown represents the CD8⁺ and tetramer⁺ population (solid bars) and the tetramer⁺ population producing IFN-γ (shaded bars). This data is a representation of two separate experiments. (B) Surface MHC class I expression on untreated LCLs or LCLs treated with either cycloheximide, citrate buffer alone, or cycloheximide and citrate buffer. LCLs were initially incubated with MHC class I–specific mAb (W6/32) followed by incubation with FITC-labeled anti–mouse Ig. The fluorescence intensity was measured by FACSCalibur™ and data were analyzed by CELLQuest™ software. The results are expressed as mean fluorescence intensity.